Primary pulmonary hypertension is a rare disease of unknown etiology. Chronic obstructive pulmonary disease, left ventricular dysfunction and disorders associated with hypoxemia frequently result in pulmonary hypertension. Treatment with a continuous intravenous infusion of prostacyclin improves exercise capacity, quality of life, hemodynamics and long-term survival in patients with primary pulmonary hypertension. Management of secondary pulmonary hypertension includes correction of the underlying cause and reversal of hypoxemia. Lung transplantation remains an option for selected patients with pulmonary hypertension that does not respond to medical management. During this discussion, the diagnosis and management of pulmonary hypertension will be presented.

This educational activity consists of recorded presentations from the 2010 Innovations in Wellness and Disease Management conference held in Las Vegas, Nevada on February 17-18, 2010. For more information on additional presentations from this event please go to, http://www.optumhealtheducation.com/cme/wellness/innovations-in-wellness-and-disease-management.

Learning Objectives
At the end of this educational activity, participants should be able to

1. Identify characteristics of pulmonary hypertension and how this condition is diagnosed.
2. State the treatment guidelines and recommendations for managing pulmonary hypertension.
3. Recognize emerging therapies to treat pulmonary hypertension.

Presenter
Robert L. Scott, MD
Director, Heart Failure Clinic
Medical Director, Cardiac Transplantation
Mayo Clinic
Phoenix, Arizona

Faculty Disclosures
As a sponsor accredited by the ACCME, the Institute for the Advancement of Human Behavior and the joint sponsor, OptumHealth Education requires the disclosure of any significant financial interest or other relationship a faculty member or sponsor has with the manufacturer(s) of any product discussed in this educational presentation. The faculty reported the following:

Robert L. Scott, MD
Consultant/Scientific Advisor: Actelion Pharmaceuticals and XDX Corporation
This conflict of interest was resolved by limiting Dr Scott to data and results.
Dr Scott does not intend to discuss unapproved/investigative use of commercial products/devices.

Disclosure of Unlabeled or Investigational Drugs
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Staff Disclosures
In compliance with the ACCME's Standards for Commercial Support, employees of OptumHealth Education who have control over content of a CME activity are required to disclose their relevant financial relationships. No employee has a relevant financial relationship regarding this activity.

Contact Information for Content, Website and/or CNE/CE Questions
OptumHealth Education
Phone: (800) 326-9166
E-mail: moreinfo@optumhealtheducation.com

Contact Information for CME Credit Questions
Sheryl Morgan
Institute for the Advancement of Human Behavior
Phone: (651) 789-3730
E-mail: shmorgan@smithbucklin.com

Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

To participate in this activity, begin by viewing the CE Info and then follow the prompts.

Sponsored By
This activity is jointly sponsored by the Institute for the Advancement of Human Behavior and OptumHealth Education.

Commercial Support
There was no commercial support received for this activity.

Hardware/Software Requirements
To view this Webcast you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+, or Adobe Flash Player 9+. Be sure to disable your pop-up blocking software.

Please see our Privacy Policy by clicking here